Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 211 of 5804
-
New personalized vaccine trial aims to boost immune attack on aggressive breast cancer
Disease control Not yet recruitingThis is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine (PCV) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative breast cancer undergoing neoadjuvant chemoimmunotherap…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental vaccine cocktail targets rare liver cancer in early trial
Disease control Not yet recruitingThe purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective r…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can Super-Heated peanuts make allergy treatment safer?
Disease control Not yet recruitingPeanut allergy can cause serious and potentially life-threatening allergic reactions. Oral immunotherapy (OIT) is an investigational treatment that involves giving small, gradually increasing amounts of peanut protein to help reduce allergic sensitivity. However, OIT may cause al…
Phase: PHASE2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One-Stop hepatitis c care could save thousands of lives
Disease control Not yet recruitingThis is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm). 1:1 randomization occurs at the site level.
Phase: PHASE4 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Not yet recruitingThe purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastat…
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Smart missile drug takes aim at Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis is an open-label, multicenter Phase 1 study of DEC003M, in patients with advanced stage prostate cancer. The study consists of a dose-escalation phase to determine the dose for expansion, followed by a dose-expansion phase to evaluate preliminary antitumor activity, safety, …
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiotherapy revolution: could 5 sessions replace 25 for endometrial cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to assess the safety and feasibility of using a new form of radiotherapy technology, known as CT online-adaptive radiotherapy, to reduce the number of treatment sessions required in post-operative radiotherapy for patients with endometrial cance…
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New biologic aims to tackle stubborn high triglycerides
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus lifestyle management. Eligible participants complete a scr…
Phase: PHASE3 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
AI reads brain tumor types from routine slides, no special stains needed
Knowledge-focused Not yet recruitingThis is a multi-center, retrospective, observational study to develop and internally validate an artificial intelligence (AI) foundation model for hierarchical classification of central nervous system (CNS) tumors using approximately 20,000 hematoxylin and eosin (H\&E) whole-slid…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Could a single iron infusion ease heart failure in seniors?
Disease control Not yet recruitingThis randomized, double-blind, placebo-controlled clinical trial evaluates intravenous ferric derisomaltose in older adults with HFpEF and iron deficiency.
Phase: PHASE4 • Sponsor: Duke University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Brain training for young hearts: new program aims to sharpen thinking in kids with congenital heart disease
Disease control Not yet recruitingChildren with complex congenital heart disease (cCHD) nowadays survive thanks to medical advances into their teenage years and adulthood. However, many of them have difficulties with so-called executive functions. These include skills such as paying attention, planning, self-cont…
Phase: NA • Sponsor: Bea Latal • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Fewer radiation sessions may be just as effective for thymic tumors after surgery
Disease control Not yet recruitingThis is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors. The study estimates 5-year local control and prospectively characteri…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Herbal granules aim to revive immune system in HIV patients
Disease control Not yet recruitingThis pragmatic randomized controlled trial evaluates whether Fuyang Jiedu Granules combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and spleen-kidney yang deficiency syndrome. Eligible…
Phase: NA • Sponsor: Beijing University of Chinese Medicine • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Herbal formula may help HIV patients whose immune systems Don't fully recover
Disease control Not yet recruitingThis pragmatic randomized controlled trial evaluates whether Qiling Yiqi Tablets combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and lung-spleen qi deficiency syndrome. Eligible parti…
Phase: NA • Sponsor: Beijing University of Chinese Medicine • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug cocktail aims to shrink tough lung cancers
Disease control Not yet recruitingThis study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with p…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study is testing a new imaging tracer called \[18F\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis. \[18F\]FAPI-74 a…
Phase: PHASE1, PHASE2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Double attack on EGFR-Positive tumors: targeted drug plus immunotherapy combo tested
Disease control Recruiting nowThis phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors. The study is designed to assess clinical efficacy and safety, bu…
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a spinal implant tame Hard-to-Control asthma?
Disease control Not yet recruitingThis study aims to assess the safety and efficacy of Pulmonary Neuromodulation in patients suffering from moderate to severe asthma
Phase: NA • Sponsor: Spiro Medical, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
Disease control Not yet recruitingThis is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients with high-risk upper tract urothelial carcinoma (UTU…
Phase: PHASE2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a targeted pill boost Chemo's power against a rare blood cancer?
Disease control Not yet recruitingThis is a single-arm, multicenter, Phase Ib/IIa study designed to explore the efficacy and safety of SHR2554 in combination with liposomal mitoxantrone for the treatment of patients with treatment-naive peripheral T-cell lymphoma (PTCL). The study is divided into a Phase Ib safet…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC